01.09.2015 Views

A Path to Prosperity New Directions for African Livestock

GALVmed Impetus Strategy Paper

GALVmed Impetus Strategy Paper

SHOW MORE
SHOW LESS
  • No tags were found...

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

4.4 Improving Animal Health<br />

Services in Rural Areas<br />

Improving veterinary services <strong>to</strong> the rural poor is a<br />

pressing need in terms of improved productivity,<br />

controlling zoonoses and putting in place<br />

mechanisms <strong>to</strong> allow the prompt detection and<br />

control of epizootics. Three <strong>to</strong>pics have been<br />

identified as key <strong>to</strong> advancing effective veterinary<br />

service delivery <strong>to</strong> rural areas.<br />

4.4.1 Assuring Quality of Veterinary<br />

Vaccines and Medicines<br />

Farmers, even poor farmers, are normally willing<br />

<strong>to</strong> pay <strong>for</strong> efficacious veterinary medicines. They<br />

also have strong brand loyalty <strong>for</strong> quality products<br />

and yet all those consulted be<strong>for</strong>e compiling this<br />

strategy paper agree that the quality of veterinary<br />

medicines reaching small farmers in Africa is<br />

poor and getting worse. The situation <strong>for</strong> larger<br />

commercial farmers is <strong>to</strong>lerable, as they generally<br />

have close links <strong>to</strong> distributers who are more likely<br />

<strong>to</strong> s<strong>to</strong>ck quality products. For small farmers, quality<br />

remains a significant issue. Most analysis on drug<br />

quality has been done on trypanocides because<br />

of the growing resistance <strong>to</strong> the limited number<br />

of compounds available <strong>to</strong> treat this disease.<br />

In countries with trypanosomosis, trypanocides<br />

represent 40–50% of the market <strong>for</strong> veterinary<br />

medicinal products 52 , worth an estimated $35–40<br />

million per annum across SSA 53 . However in<br />

West Africa, analysis showed that 70–100% of<br />

trypanocides did not con<strong>for</strong>m <strong>to</strong> what was stated<br />

<strong>to</strong> be in the product according <strong>to</strong> the data sheet<br />

supplied 59 . Similar analysis of other therapeutic<br />

groups suggests as many as two thirds of antibiotics<br />

and anthelmintics do not con<strong>for</strong>m. This includes<br />

products bought from <strong>for</strong>mal and in<strong>for</strong>mal markets.<br />

Analysis carried out in East Africa showed that<br />

some anthelmintics contained no active ingredient<br />

at all and the researchers concluded that "many<br />

anthelmintic preparations marketed in Kenya are<br />

clearly of very poor quality” 54 .<br />

In addition <strong>to</strong> development of drug resistance,<br />

drug quality is vital because the poor can’t af<strong>for</strong>d<br />

<strong>to</strong> waste their money on sub-standard products.<br />

Those small farmers who invest in improving<br />

the quality of their s<strong>to</strong>ck, either nutritionally,<br />

genetically or through improved housing, need<br />

veterinary products <strong>to</strong> protect their investments<br />

and match their improved outputs. Whilst it is<br />

difficult <strong>for</strong> private vets and veterinary<br />

para-professionals <strong>to</strong> build reputations when<br />

selling sub-standard products, industry<br />

commenta<strong>to</strong>rs state that many vendors of<br />

veterinary drugs knowingly sell sub-standard<br />

products either because the profit margins are<br />

higher or because they can’t compete on price if<br />

they s<strong>to</strong>ck quality products. It appears <strong>to</strong> be a race<br />

<strong>to</strong> the bot<strong>to</strong>m with lack of regulation and reduced<br />

purchasing power speeding up the process.<br />

Furthermore, major pharmaceutical companies<br />

are unwilling <strong>to</strong> invest in research and<br />

commercialisation of new Africa-specific products<br />

if they risk being undermined by the inability<br />

of national authorities <strong>to</strong> protect their investment<br />

from counterfeits, doc<strong>to</strong>ring of the product and<br />

generic copies.<br />

Lack of functioning regula<strong>to</strong>ry and quality control<br />

mechanisms are a key concern 55 . West <strong>African</strong><br />

commenta<strong>to</strong>rs cited lack of legislation <strong>for</strong> veterinary<br />

medicines 56 as a key driver <strong>to</strong> improved and<br />

harmonised legislation 57 . In east and southern<br />

Africa, industry representatives state that legislation<br />

is adequate, what is missing is the capacity <strong>to</strong><br />

en<strong>for</strong>ce the regulations 58 . Chronically underfunded<br />

and weak registration authorities remain a fac<strong>to</strong>r<br />

in poor quality control, as the parameters <strong>for</strong><br />

registration are either poorly defined or not utilised<br />

and unregistered products are not removed from<br />

the market. Senegal, <strong>for</strong> example, has 140<br />

veterinary drugs registered but more than 1000<br />

different veterinary drugs marketed 59 . This is typical<br />

of most countries in SSA, with the exception of<br />

S. Africa and Namibia 58 .<br />

The Impetus Strategy Paper I Page 27

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!